Skip to content

Lobbying by Alexion Pharma Canada Corp.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Alexion Pharma Canada Corp.

Meetings this Parliament
0
With MPs
0
Since Nov 2021
0
Active registrations
1

Registrations in effect

Consultant In effect since Jun 12, 2026

Consultant William Dempster of 3Sixty Public Affairs Inc.

Consultant lobbyists

  • William Dempster Former public office holder

    Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)

Institutions they may lobby: Finance Canada (FIN), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Senate of Canada

What they're lobbying on (7)
  • Bill C-64: An Act respecting pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies.
  • Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
  • Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
  • Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board.
  • Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy.
  • Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including addressing any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.
  • Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Registration 778465-372825-3. Look it up in the official Registry

Reported meetings

No meetings reported since November 2021.

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.